Premium
Letter: ACE2, IBD and COVID‐19—why IBD patients may be at reduced risk of COVID‐19
Author(s) -
Prentice Ralley E.,
Tjandra Doug,
Garg Mayur,
Lubel John S.,
Fourlanos Spiros,
Johnson Doug,
AlAni Aysha,
Christensen Britt
Publication year - 2020
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.16063
Subject(s) - covid-19 , medicine , coronavirus infections , betacoronavirus , medline , pandemic , inflammatory bowel diseases , virology , ulcerative colitis , disease , outbreak , infectious disease (medical specialty) , biology , biochemistry
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom